The midbrain slice preparation. An in vitro model to select potential anti-parkinsonian drugs?

Parkinsonism and Related Disorders

Volumn 14, Issue SUPPL.2, 2008, Pages

  Guatteo, Ezia ^a   Cucchiaroni, Maria Letizia ^a,b   Sebastianelli, Luca ^a,b   Bernardi, Giorgio ^a,b   Mercuri, Nicola Biagio ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Dopamine agonists; Electrophysiology; In vitro model; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINEPTINE; AMPHETAMINE; ANTIPARKINSON AGENT; BROMOCRIPTINE; COCAINE; DOPAMINE RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; HALOPERIDOL; LEVODOPA; LISURIDE; METHYLPHENIDATE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; NOMIFENSINE; OXIDOPAMINE; PERGOLIDE; PHENYLALANINE; PRAMIPEXOLE; QUINPIROLE; SELEGILINE; TYRAMINE;

ARTICLE; BRAIN SLICE; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; ELECTROPHYSIOLOGY; IN VITRO STUDY; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE; DOPAMINE AGENTS; ELECTROPHYSIOLOGY; HUMANS; MESENCEPHALON; NEURONS;

EID: 47049123152     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.04.020     Document Type: Article

References (31)

1. Birkmayer W., and Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (l-DOPA) on akinesia in parkinsonism. Wien Klin Wochenschr 73 (1961) 787-788
2. Nomoto M., Jenner P., and Marsden C.D. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci Lett 57 1 (1985) 37-41
3. Mercuri N.B., Calabresi P., and Bernardi G. Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease. Neurology 39 8 (1989) 1106-1108
4. Sanghera M.K., Trulson M.E., and German D.C. Electrophysiological properties of mouse dopamine neurons: in vivo and in vitro studies. Neuroscience 12 3 (1984) 793-801
5. Kita T., Kita H., and Kitai S.T. Electrical membrane properties of rat substantia nigra compacta neurons in an in vitro slice preparation. Brain Res 372 1 (1986) 21-30
6. Bergquist F., Shahabi H.N., and Nissbrandt H. Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod. Brain Res 973 1 (2003) 81-91
7. Andersson D.R., Nissbrandt H., and Bergquist F. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. Eur J Neurosci 24 2 (2006) 617-624
8. Fleming S.M., Fernagut P.O., and Chesselet M.F. Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2 3 (2005) 495-503
9. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367 (1971) 69-93
10. Jenner P., Rupniak N.M., Rose S., Kelly E., Kilpatrick G., Lees A., et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 50 1-3 (1984) 85-90
11. Langston J.W., Forno L.S., Rebert C.S., and Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 292 2 (1984) 390-394
12. Lane E, Dunnett S. Animal models of Parkinson's disease and l-dopa induced dyskinesia: how close are we to the clinic? Psychopharmacology (Berl), published online 25 Sept 2007, DOI: 10.1007/s00213-007-0931-8.
13. McNaught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56 1 (2004) 149-162
14. Schapira A.H., Cleeter M.W., Muddle J.R., Workman J.M., Cooper J.M., and King R.H. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 60 2 (2006) 253-255
15. Zeng B.Y., Bukhatwa S., Hikima A., Rose S., and Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol 60 2 (2006) 248-252
16. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H.J., et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 60 2 (2006) 260-264
17. Uversky V.N. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318 1 (2004) 225-241
18. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 4 (2002) 308-318
19. Mercuri N.B., Bonci A., and Bernardi G. Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs. Trends Pharmacol Sci 18 7 (1997) 232-235
20. Aghajanian G.K., and Bunney B.S. Pharmacological characterization of dopamine "autoreceptors" by microiontophoretic single-cell recording studies. Adv Biochem Psychopharmacol 16 (1977) 433-438
21. Mercuri N.B., Calabresi P., and Bernardi G. Responses of rat substantia nigra compacta neurones to l-DOPA. Br J Pharmacol 100 2 (1990) 257-260
22. Mercuri N.B., Calabresi P., and Bernardi G. The electrophysiological actions of dopamine and dopaminergic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area. Life Sci 51 10 (1992) 711-718
23. Geracitano R., Federici M., Bernardi G., and Mercuri N.B. On the effects of psychostimulants, antidepressants, and the antiparkinsonian drug levodopa on dopamine neurons. Ann N Y Acad Sci 1074 (2006) 320-329
24. Piercey M.F., Hoffmann W.E., Smith M.W., and Hyslop D.K. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312 1 (1996) 35-44
25. Pinnock R.D. Action of putative dopamine receptor agonists, TL-99, 3-PPP and RDS-127 on substantia nigra neurons. Brain Res 292 1 (1984) 190-193
26. Seutin V., Scuvee-Moreau J., Giesbers I., Massotte L., and Dresse A. Effect of BHT 920 on monoaminergic neurons of the rat brain: an electrophysiological in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol 342 5 (1990) 502-507
27. Cardozo D.L. Midbrain dopaminergic neurons from postnatal rat in long-term primary culture. Neuroscience 56 2 (1993) 409-421
28. Bowery B., Rothwell L.A., and Seabrook G.R. Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br J Pharmacol 112 3 (1994) 873-880
29. Mercuri N.B., Bonci A., Siniscalchi A., Stefani A., Calabresi P., and Bernardi G. Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an in vitro study. Br J Pharmacol 117 3 (1996) 528-532
30. Mercuri N.B., Scarponi M., Federici M., Bonci A., Siniscalchi A., and Bernardi G. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease. Ann Neurol 43 5 (1998) 613-617
31. Birkmayer W., Riederer P., Youdim M.B., and Linauer W. The potentiation of the anti akinetic effect after l-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 36 3-4 (1975) 303-326